Cobra Biologics has partnered with the Karolinska Institutet in Sweden to develop a potential DNA vaccine candidate for the novel coronavirus, SARS-CoV-2.
Under OPENCORONA consortium supporting the fight against Covid-19, the partners received €3m emergency funding from the Europe Union’s Horizon 2020.
The funds are intended to support research and development and Phase I trial of a vaccine. OPENCORONA consortium also comprises Karolinska University Hospital, Public Health Authority (FoHM), IGEA, Adlego and Giessen University.
The project aims to produce a DNA vaccine that will be administered via the patient’s muscle. The vaccine will generate a viral antigen for the immune system to react on.